Why the study?
Off-label DOAC dosing is clinically encountered in AF patients, but data on the clinical outcomes of over- and under-dosing are lacking in Japan.
Does off-label DOAC dosing affect the risk of adverse clinical events in Japanese patients with atrial fibrillation?
Does off-label DOAC dosing affect the risk of adverse clinical events in Japanese patients with atrial fibrillation?
In Japanese patients with atrial fibrillation, off-label under-dosing of DOACs does not worsen clinical outcomes and may reduce bleeding, whereas over-dosing significantly increases the risk of adverse events.
No takes yet. Share an insight, caveat, or question.
Under-dosing associated with similar efficacy and possibly less bleeding, over-dosing with more events in Japanese AF; leaves open need for randomized confirmation.
Murata et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: